Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alteplase vs Placebo for Symptomatic Septated Malignant Pleural Effusion
NCT06184321Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Feb 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised trial in malignant pleural effusion (MPE) comparing Arm I (alteplase) with Arm II (placebo) (2 arms). Primary endpoints: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events at 1 year and Evaluation of dyspnea using the visual analog scale (VAS) at 1 week. Started Aug 2023; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT06184321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184321.